Literature DB >> 19160671

Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt.

Abdelkader Essafi1, Ana R Gomes, Karen M Pomeranz, Aleksandra K Zwolinska, Rana Varshochi, Ursula B McGovern, Eric W-F Lam.   

Abstract

This chapter describes methods for studying downstream events of the PI3K/Akt signaling cascade, focusing on the FoxO transcription factors. These approaches also represent alternative means for gauging the phosphoinositide-3 kinase/Akt activity. We describe protocols for the fractionation of cytoplasmic and nuclear protein extracts and for studying transcription factor DNA-binding activity in vitro and in vivo.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19160671     DOI： 10.1007/978-1-60327-115-8_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  8 in total

1.  Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate.

Authors:  D Davila; N M C Connolly; H Bonner; P Weisová; H Dussmann; C G Concannon; H J Huber; J H M Prehn
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

2.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

3.  Astrocyte Resilience to Oxidative Stress Induced by Insulin-like Growth Factor I (IGF-I) Involves Preserved AKT (Protein Kinase B) Activity.

Authors:  David Dávila; Silvia Fernández; Ignacio Torres-Alemán
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.157

4.  ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.

Authors:  Yoshiya Horimoto; Johan Hartman; Julie Millour; Steven Pollock; Yolanda Olmos; Ka-Kei Ho; R Charles Coombes; Matti Poutanen; Sari I Mäkelä; Mona El-Bahrawy; Valerie Speirs; Eric W-F Lam
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

5.  ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Authors:  Julie Millour; Natalia de Olano; Yoshiya Horimoto; Lara J Monteiro; Julia K Langer; Rosa Aligue; Nabil Hajji; Eric W F Lam
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

6.  Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin.

Authors:  Ka-Kei Ho; Victoria A McGuire; Chuay-Yeng Koo; Kyle W Muir; Natalia de Olano; Evie Maifoshie; Douglas J Kelly; Ursula B McGovern; Lara J Monteiro; Ana R Gomes; Angel R Nebreda; David G Campbell; J Simon C Arthur; Eric W-F Lam
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

7.  FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.

Authors:  C T Karadedou; A R Gomes; J Chen; M Petkovic; K-K Ho; A K Zwolinska; A Feltes; S Y Wong; K Y K Chan; Y-N Cheung; J W H Tsang; J J Brosens; U-S Khoo; E W-F Lam
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

8.  Estrogen receptor α-coupled Bmi1 regulation pathway in breast cancer and its clinical implications.

Authors:  Huali Wang; Haijing Liu; Xin Li; Jing Zhao; Hong Zhang; Jingzhuo Mao; Yongxin Zou; Hong Zhang; Shuang Zhang; Wei Hou; Lin Hou; Michael A McNutt; Bo Zhang
Journal:  BMC Cancer       Date:  2014-02-24       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.